L7 STRUCTURE UPLOADED

=> d l7
L7 HAS NO ANSWERS
L7 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l7
SAMPLE SEARCH INITIATED 14:08:42 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 44 TO ITERATE

100.0% PROCESSED 44 ITERATIONS 27 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 483 TO 1277
PROJECTED ANSWERS: 229 TO 851

L8 27 SEA SSS SAM L7

=> s l7 ful
FULL SEARCH INITIATED 14:08:51 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 736 TO ITERATE

100.0% PROCESSED 736 ITERATIONS 420 ANSWERS
SEARCH TIME: 00.00.01

L9 420 SEA SSS FUL L7

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION

FULL ESTIMATED COST 185.88 562.84

FILE 'CAPLUS' ENTERED AT 14:08:56 ON 09 SEP 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 9 Sep 2009 VOL 151 ISS 11
FILE LAST UPDATED: 8 Sep 2009 (20090908/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2009

CAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

The ALL, BIB, MAX, and STD display formats in the CA/CAplus family of databases have been updated to include new citing references information. This enhancement may impact record import into database management software. For additional information, refer to NEWS 9.

=> s l9
L10 3 L9

=> d abs fbib fhitstr 1-3

L10 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN
AB The present invention provides pharmaceutical combinations that include small mol. immune response modifiers (IRMs) formulated for mucosal administration and an antigen formulated for mucosal administration. Addnl., the invention provides methods for immunizing a subject. Generally, the methods include administering an antigen to a mucosal surface of the subject in an amount effective, in combination with an IRM compound, to generate an immune response against the antigen; and administering an IRM compound to a mucosal surface of the subject in an amount effective, in combination with the antigen, to generate an immune response against the antigen. For example, an ovalbumin-IRM1 (N-[6-[[2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]

1,1-dimethylethyl]amino]-6-oxohexyl]-4-azido-2-hydroxybenzamide) conjugate was prepared and suspended in PBS to a final concentration of 5 mg/mL ovalbumin and
0.5 mg/mL IRM1. Mice were immunized on Day 0 with 100 μg of the ovalbumin-IRM1 conjugate, either intranasally or i.v. Intranasal delivery of antigen plus IRM1 generated greater total ovalbumin-specific CD8+ T cell (OT-I) nos. at Day 7 than i.v. delivery in all lymphoid tissues examined Also, intranasal delivery of IRM1 plus antigen generated greater total OT-I cell nos. at Day 7 than antigen alone, indicating a dramatic effect of the IRM in enhancing antigen specific T cell activation via that route.

AN 2006:216958 CAPLUS
DN 144:299305
TI Compositions comprising nitrogen-containing heterocycle immune response modifiers for mucosal vaccination
IN Miller, Richard L.; Kieper, William C.
PA 3M Innovative Properties Company, USA
SO U.S. Pat. Appl. Publ., 20 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	US 20060051374	A1	20060309	US 2005-116476		20050428
				US 2004-566121P	P	20040428
	CA 2564855	A1	20051028	CA 2005-2564855		20050428
				US 2004-566121P	P	20040428
				WO 2005-US14746	W	20050428
	WO 2006126981	A2	20061130	WO 2005-US14746		20050428
	WO 2006126981	A3	20090409			
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA					
				US 2004-566121P	P	20040428
	AU 2005331250	A1	20061214	AU 2005-331250		20050428
				US 2004-566121P	P	20040428
	EP 1755665	A2	20070228	EP 2005-857870		20050428
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU					
				US 2004-566121P	P	20040428
				WO 2005-US14746	W	20050428
	BR 2005010430	A	20071030	BR 2005-10430		20050428
				US 2004-566121P	P	20040428
				WO 2005-US14746	W	20050428
	JP 2008505857	T	20080228	JP 2007-518053		20050428

			US 2004-566121P	P	20040428
			WO 2005-US14746	W	20050428
MX 2006012451	A	20070131	MX 2006-12451		20061026
			US 2004-566121P	P	20040428
			WO 2005-US14746	W	20050428
CN 101426524	A	20090506	CN 2005-80013768		20061030
			US 2004-566121P	P	20040428
			WO 2005-US14746	W	20050428
IN 2006CN04378	A	20070615	IN 2006-CN4378		20061128
			WO 2005-US14746	W	20050428

IT 859875-28-8, IRM 6
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. comprising antigen and aminopyridine fused to five membered nitrogen-containing heterocycle as immune modifier for mucosal vaccination)

RN 859875-28-8 CAPLUS

CN 1H-Imidazo[4,5-c]quinoline-1-propanesulfonamide, 4-amino-2-(ethoxymethyl)-N,β,β-trimethyl- (CA INDEX NAME)



L10 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN

GI



I



II

AB Title compds. I [X = CHR9, CHR9-alkylene, CHR9-alkenylene wherein alk(en)ylene are optionally interrupted by one or more O; R9 = H, alkyl; R1, R1' = independently H, (un)substituted alk(en)yl, hetero/aryl, etc.; or R1NR1' = nitrogen saturated ring; R'' = H, non-interfering substituent; RA, RB = independently H, halo, alk(en)yl, alkoxy, alkythio, NH2 and derivs.; or RBCCRA = (un)substituted fused hetero/aryl; and their pharmaceutically acceptable salts], were prepared as immunomodulators for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases. For example, II (m.p. = 225-228°) was prepared in 5 steps by amination of 4-chloro-3-nitroquinoline with N-methyl-3-aminopropane-1-sulfonamide•HCl, hydrogenation, cyclization of 1,2-diamine with tri-Et orthopropionate, and oxidation, and amination of the N-oxide (not isolated) with NH4OH. Certain I may modulate cytokine biosynthesis by inhibiting production of interferon α and/or tumor necrosis factor TNF-α when tested in an in vitro blood cell system (no data).

AN 2005:638876 CAPLUS

DN 143:153375

TI Preparation of imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides as inducers of cytokine biosynthesis for treatment of viral and neoplastic diseases

IN Bonk, Jason D.; Dellaria, Joseph F., Jr.

PA 3M Innovative Properties Company, USA

SO PCT Int. Appl., 226 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI	WO 2005066169	A2	20050721	WO 2004-US43447	20041223
	WO 2005066169	A3	20051110		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2003-533465P	P 20031230
				US 2004-555936P	P 20040324
				US 2004-581335P	P 20040618
	AU 2004312508	A1	20050721	AU 2004-312508	20041223
				US 2003-533465P	P 20031230
				US 2004-555936P	P 20040324
				US 2004-581335P	P 20040618
				WO 2004-US43447	W 20041223
	CA 2551399	A1	20050721	CA 2004-2551399	20041223
				US 2003-533465P	P 20031230
				US 2004-555936P	P 20040324
				US 2004-581335P	P 20040618
				WO 2004-US43447	W 20041223
	EP 1699788	A2	20060913	EP 2004-815514	20041223
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
				US 2003-533465P	P 20031230
				US 2004-555936P	P 20040324
				US 2004-581335P	P 20040618
				WO 2004-US43447	W 20041223
	JP 2007517044	T	20070628	JP 2006-547410	20041223
				US 2003-533465P	P 20031230
				US 2004-555936P	P 20040324
				US 2004-581335P	P 20040618
				WO 2004-US43447	W 20041223
	CN 101014596	A	20070808	CN 2004-80042087	20041223
				US 2003-533465P	P 20031230
				US 2004-555936P	P 20040324
				US 2004-581335P	P 20040618
				WO 2004-US43447	W 20041223
	US 20090062272	A1	20090305	US 2006-596897	20060628
				US 2003-533465P	P 20031230
				US 2004-555936P	P 20040324
				US 2004-581335P	P 20040618
				WO 2004-US43447	W 20041223
	IN 2006CN02383	A	20070706	IN 2006-CN2383	20060630
				US 2003-533465P	P 20031230
				WO 2004-US43447	W 20041223
OS	CASREACT 143:153375; MARPAT 143:153375				
IT	859874-33-2				
	RL: PRPH (Prophetic)				

(Preparation of imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides as inducers of cytokine biosynthesis for treatment of viral and neoplastic diseases)

RN 859874-33-2 CAPLUS

CN 1H-Imidazo[4,5-c]quinoline-1-butanesulfonamide, 4-amino-2-ethyl- (CA INDEX NAME)



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN

GI



I

AB Title compds. I (R = alkyl, alkoxy, OH, CF3; n = 0, 1; R1, R2 = H, non-interfering substituent; R3 = ArZ, aminosulfonylaryl, aminocarbonylaryl, etc.; Ar = aryl, heteroaryl; Z = bond, alkylene, alkenylene, alkynylene) which are immunomodulators, inducing cytokines biosynthesis, and inhibiting tumor necrosis factors biosynthesis, are prepared For example, 2-butyl-1-isobutyl-7-(thiophen-3-yl)-1H-imidazo[4,5-c]quinolin-4-amine was prepared in a multi-step synthesis starting from 3-bromoaniline, tri-Et orthoformate, and Meldrum's acid. I are useful in the treatment of viral and neoplastic diseases.

AN 2004:566606 CAPLUS

DN 141:123628

TI Preparation of aryl/heteroaryl substituted imidazoquinolines as immunomodulators

IN Hays, David S.; Niwas, Shri; Kshirsagar, Tushar; Ghosh, Tarun K.; Gupta, Shalley K.; Heppner, Philip D.; Merrill, Bryon A.; Bonk, Jason D.; Danielson, Michael E.; Gerster, John F.; Haraldson, Chad A.; Johannessen, Sarah C.; Kavanagh, Maureen A.; Lindstrom, Kyle J.; Prince, Ryan B.; Radmer, Matthew R.; Rice, Michael J.; Squire, David J.; Strong, Sarah A.; Wurst, Joshua R.

PA 3M Innovative Properties Company, USA

SO PCT Int. Appl., 465 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	WO 2004058759	A1	20040715	WO 2003-US40373		20031218
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW					
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
				US 2002-435889P	P	20021220
				US 2003-516331P	P	20031031
	CA 2510375	A1	20040715	CA 2003-2510375		20031218
				US 2002-435889P	P	20021220
				US 2003-516331P	P	20031031
				WO 2003-US40373	W	20031218
	AU 2003301052	A1	20040722	AU 2003-301052		20031218
				US 2002-435889P	P	20021220
				US 2003-516331P	P	20031031
				WO 2003-US40373	W	20031218
	US 20040147543	A1	20040729	US 2003-739787		20031218
	US 7091214	B2	20060815			
				US 2002-435889P	P	20021220
				US 2003-516331P	P	20031031
	EP 1590348	A1	20051102	EP 2003-814164		20031218
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
				US 2002-435889P	P	20021220
				US 2003-516331P	P	20031031
				WO 2003-US40373	W	20031218
	CN 1747953	A	20060315	CN 2003-80109659		20031218
				US 2002-435889P	P	20021220
				US 2003-516331P	P	20031031
	JP 2006513212	T	20060420	JP 2004-563764		20031218
				US 2002-435889P	P	20021220
				US 2003-516331P	P	20031031
				WO 2003-US40373	W	20031218
	NZ 540826	A	20080731	NZ 2003-540826		20031218
				US 2002-435889P	P	20021220

				US 2003-516331P	P 20031031
				WO 2003-US40373	W 20031218
MX 2005006740	A	20051005	MX 2005-6740		20050617
			US 2002-435889P	P	20021220
			US 2003-516331P	P	20031031
			WO 2003-US40373	W	20031218
IN 2005CN01348	A	20070727	IN 2005-CN1348		20050620
			US 2002-435889P	P	20021220
			WO 2003-US40373	W	20031218
ZA 2005005787	A	20061227	ZA 2005-5787		20050719
			US 2002-435889P	P	20021220
US 20060111387	A1	20060525	US 2006-275553		20060113
			US 2002-435889P	P	20021220
			US 2003-516331P	P	20031031
			US 2003-739787	A3	20031218
IN 2008CN00052	A	20080919	IN 2008-CN52		20080104
			US 2002-435889P	P	20021220
			WO 2003-US40373	W	20031218
			IN 2005-CN1348	A3	20050620

OS MARPAT 141:123628

IT 723283-23-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of imidazoquinoline derivs. as immunomodulators for treatment of viral and antineoplastic diseases)

RN 723283-23-6 CAPLUS

CN 1H-Imidazo[4,5-c]quinoline-1-pentanesulfonamide, 4-amino-7-bromo-2-(ethoxymethyl)-N,N-dimethyl- (CA INDEX NAME)



OSC.G 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)